SCYNEXIS (LTS:0L49) Debt-to-Equity : 0.04 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is SCYNEXIS Debt-to-Equity?

SCYNEXIS's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.4 Mil. SCYNEXIS's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $2.5 Mil. SCYNEXIS's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $74.1 Mil. SCYNEXIS's debt to equity for the quarter that ended in Mar. 2024 was 0.04.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for SCYNEXIS's Debt-to-Equity or its related term are showing as below:

LTS:0L49' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.64 Med: 0.68 Max: 15.03
Current: 0.04

During the past 12 years, the highest Debt-to-Equity Ratio of SCYNEXIS was 15.03. The lowest was -1.64. And the median was 0.68.

LTS:0L49's Debt-to-Equity is ranked better than
84.2% of 848 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs LTS:0L49: 0.04

SCYNEXIS Debt-to-Equity Historical Data

The historical data trend for SCYNEXIS's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SCYNEXIS Debt-to-Equity Chart

SCYNEXIS Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

1.15

0.87

1.06

15.03

0.21

SCYNEXIS Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															-1.64	0.16	0.16	0.21	0.04

Competitive Comparison of SCYNEXIS's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SCYNEXIS's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where SCYNEXIS's Debt-to-Equity falls into.

SCYNEXIS Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

SCYNEXIS's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.34	+	14.74)	/	72.962
	=	0.21

SCYNEXIS's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.356	+	2.487)	/	74.105
	=	0.04

SCYNEXIS (LTS:0L49) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

SCYNEXIS Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of SCYNEXIS's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

SCYNEXIS (LTS:0L49) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SCYNEXIS Inc (LTS:0L49) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

SCYX:USA 135A:Germany

Address

1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548

Website

https://www.scynexis.com

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.

SCYNEXIS (LTS:0L49) Headlines

No Headlines